SFI
PPBT

Susquehanna Fundamental Investments’s Purple Biotech PPBT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-144
Closed -$110K – 1600
2020
Q4 		$110K Hold
144
– – ﹤0.01% 1418
2020
Q3 		$127K Buy
+144
New +$178K ﹤0.01% 1256

Other funds holding PPBT

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WTB
Washington Trust Bank Spokane, Washington $1.43B AUM 25.27% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Susquehanna Fundamental Investments's PPBT Position: Q1 2021 in Review

Susquehanna Fundamental Investments sold out of Purple Biotech (PPBT) in Q1 2021, closing a stake of 144 shares — an estimated $110K sold.

Susquehanna Fundamental Investments first reported a position in PPBT in Q3 2020 and held it in 2 quarters. The position peaked at $127K in Q3 2020. 15 funds tracked by Wall St. Rank hold PPBT as of Q1 2021.

  • Susquehanna Fundamental Investments reported no remaining Purple Biotech position as of Q1 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 144 Purple Biotech shares in Q1 2021, an estimated $110K.
  • Susquehanna Fundamental Investments first reported a position in Purple Biotech in Q3 2020 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Purple Biotech position peaked at $127K in Q3 2020.
  • 15 funds tracked by Wall St. Rank held Purple Biotech as of Q1 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2021, filed 17 May 2021.